A promising genomic signature that may predict for patients with ER+HER2- breast cancer with favorable tumor biology in whom radiation therapy may be able to be omitted is the 16-gene Profile for the Omission of Local Adjuvant Radiation (POLAR) [49]. This evidence concerns the gene ERBB2 and breast cancer.